|
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
21 gevonden resultaten
| nr | titel | auteur | tijdschrift | jaar | jaarg. | afl. | pagina('s) | type |
| 1 | Author index |
2016 |
44 | S1 |
p. S12- 1 p. |
artikel |
||
| 2 | Diagnostics of MPNs – to be or not to be? |
Haferlach, T. |
2016 |
44 | S1 |
p. S2-S3 2 p. |
artikel |
|
| 3 | Everything you always wanted to know about MPN but were afraid to ask |
Petrides, Petro E. |
2016 |
44 | S1 |
p. S1-S2 2 p. |
artikel |
|
| 4 | Hydroxyurea significantly increases skin toxicity in patients with MPN |
Griesshammer, M. |
2016 |
44 | S1 |
p. S8-S9 2 p. |
artikel |
|
| 5 | Interferon-alfa – 30 years of clinical experience |
Hasselbalch, H.C. |
2016 |
44 | S1 |
p. S3-S4 2 p. |
artikel |
|
| 6 | Is it time to change thrombosis risk assessment for ET and PV? |
Feistritzer, C. |
2016 |
44 | S1 |
p. S5-S6 2 p. |
artikel |
|
| 7 | Is it time to make interferon-alfa first-line therapy? |
Kiladjian, J.J. |
2016 |
44 | S1 |
p. S9-S10 2 p. |
artikel |
|
| 8 | Is polycythemia vera curable with recombinant interferon alfa (rIFNα)? |
Silver, R.T. |
2016 |
44 | S1 |
p. S10- 1 p. |
artikel |
|
| 9 | MPL/JAK2: from one signaling pathway to several disorders |
Vainchenker, W. |
2016 |
44 | S1 |
p. S2- 1 p. |
artikel |
|
| 10 | MPN and transplantation |
Kröger, N. |
2016 |
44 | S1 |
p. S11- 1 p. |
artikel |
|
| 11 | MPN and transplantation |
Clausen, J. |
2016 |
44 | S1 |
p. S10-S11 2 p. |
artikel |
|
| 12 | Necessary paradigm shifts in MPN |
Gastl, J. |
2016 |
44 | S1 |
p. S3- 1 p. |
artikel |
|
| 13 | [No title] |
Gisslinger, Heinz |
2016 |
44 | S1 |
p. v- 1 p. |
artikel |
|
| 14 | Optimizing therapy for PV: from hydroxyurea to interferon |
Burgstaller, S. |
2016 |
44 | S1 |
p. S9- 1 p. |
artikel |
|
| 15 | Patterns of presentation of thrombosis in contemporary patients with PV and ET |
Barbui, T. |
2016 |
44 | S1 |
p. S5- 1 p. |
artikel |
|
| 16 | Potential toxicities of novel drugs in the management of MPN |
Wolf, D. |
2016 |
44 | S1 |
p. S8- 1 p. |
artikel |
|
| 17 | Role for new drugs in ET and PV |
Mesa, R.A. |
2016 |
44 | S1 |
p. S4-S5 2 p. |
artikel |
|
| 18 | The impact of thrombophilia in the management of MPN |
Schwarz, J. |
2016 |
44 | S1 |
p. S6-S7 2 p. |
artikel |
|
| 19 | The role of CALR mutations in the pathogenesis of MPNs |
Kralovics, Robert |
2016 |
44 | S1 |
p. S2- 1 p. |
artikel |
|
| 20 | Treatment of high risk ET – data from the EXELS study |
Birgegård, G. |
2016 |
44 | S1 |
p. S7-S8 2 p. |
artikel |
|
| 21 | Update on PEGINVERA and PROUD-PV studies |
Gisslinger, H. |
2016 |
44 | S1 |
p. S9- 1 p. |
artikel |
21 gevonden resultaten